Kyle LaHucik

At­las Ven­ture, one of biotech’s go-to VC firms, is eye­ing a $450 mil­lion 14th fund, part­ner Bruce Booth said in its an­nu­al re­view pre­sen­ta­tion. …

No­var­tis is mak­ing an­oth­er pact in ra­dio­phar­ma, promis­ing as much as $745 mil­lion to a Boston-based start­up. Ra­tio Ther­a­peu­tics will get an undis­closed up­front pay­ment

San Diego biotech Aven­zo Ther­a­peu­tics has se­cured the ex­clu­sive op­tion to in-li­cense an­oth­er as­set, this time look­ing at glob­al ex-Chi­na rights to a bis­pe­cif­ic in

Sum­mit Ther­a­peu­tics and its Chi­nese part­ner Ake­so have a few com­peti­tors now. Mer­ck, the mak­er of the drug they’re try­ing to beat, is en­ter­ing the

The amylin field is heat­ing up ahead of No­vo Nordisk’s much-an­tic­i­pat­ed Ca­griSe­ma read­out lat­er this year. On Wednes­day, Gubra said peo­ple … Sign up to

A lot of Am­gen’s fu­ture rides on its ex­per­i­men­tal obe­si­ty med­i­cine Mar­i­Tide. At least in the minds of in­vestors. Ahead of the bio­phar­ma’s most crit­i­cal